BioWorld A closer look BioWorld Asia BioWorld Science

BioWorld

Evommune, Nektar soar on atopic dermatitis phase II data
Marking an important day for those with atopic dermatitis, shares of two biopharmas surged on clinical data suggesting new biologics are on their way to help address 40% of...

More in BioWorld

A closer look

Cancer index surges 72% as Terns, Olema lead gains
The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow Jones Industrial Average (up 12.97%). The year...

More in A closer look

BioWorld Science

ATF6 shapes liver cancer: from ER stress to inflammation
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, representing approximately 75-85% of all cases. Often considered preventable, primary liver...

More in BioWorld Science

BioWorld Asia

Innovent-Lilly $8.5B deal signals new China inflection point
The scale of the $8.5 billion deal signed between Innovent Biologics Inc. and Eli Lilly and Co. is eye-catching, but the structure is the real signal. By shifting phase II...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.